Crowder Scott, Kirkegaard Karla
Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305-5124, USA.
Nat Genet. 2005 Jul;37(7):701-9. doi: 10.1038/ng1583. Epub 2005 Jun 19.
The high error rates of viral RNA-dependent RNA polymerases create heterogeneous viral populations whose disparate RNA genomes affect each other's survival. We systematically screened the poliovirus genome and identified four sets of dominant mutations. Mutated alleles in capsid- and polymerase-coding regions resulted in dominant negative phenotypes, probably due to the proteins' oligomeric properties. We also identified dominant mutations in an RNA element required for priming RNA synthesis (CRE) and in the protein primer (VPg), suggesting that nonproductive priming intermediates are inhibitory. Mutations that inhibit the activity of viral proteinase 2A were dominant, arguing that inhibition of its known intramolecular activity creates a toxic product. Viral products that, when defective, dominantly interfere with growth of nondefective viruses will probably be excellent drug targets because drug-sensitive viruses should be dominant over drug-resistant variants. Accordingly, a virus sensitive to anticapsid compound WIN51711 dominantly inhibited the intracellular growth of a drug-resistant virus. Therefore, dominant inhibitor screening should validate or predict targets for antiviral therapy with reduced risk for drug resistance.
病毒RNA依赖性RNA聚合酶的高错误率会产生异质病毒群体,其不同的RNA基因组会相互影响彼此的存活。我们系统地筛选了脊髓灰质炎病毒基因组,并鉴定出四组主要突变。衣壳编码区和聚合酶编码区的突变等位基因导致显性负性表型,这可能是由于蛋白质的寡聚特性所致。我们还在引发RNA合成所需的RNA元件(CRE)和蛋白质引物(VPg)中鉴定出主要突变,这表明无生产性的引发中间体具有抑制作用。抑制病毒蛋白酶2A活性的突变具有显性,这表明抑制其已知的分子内活性会产生有毒产物。有缺陷时会显性干扰无缺陷病毒生长的病毒产物可能是极佳的药物靶点,因为对药物敏感的病毒应该会优于耐药变体。因此,对衣壳化合物WIN51711敏感的病毒会显性抑制耐药病毒在细胞内的生长。因此,显性抑制剂筛选应该能够验证或预测抗病毒治疗的靶点,从而降低耐药风险。